J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval

Could Offer Option As CAR-T Manufacturing Lags

 
• By Mandy Jackson

Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.

Spectrum of stacked multi-colored wooden blocks
Tecvayli is another building block in J&J/Janssen's growing multiple myeloma portfolio • Source: Shutterstock

More from New Products

More from Scrip